Feasibility of high-throughput drug sensitivity screening (hds)-guided treatment for children with refractory or relapsed acute myeloid leukemia

HIGHLIGHTS

• who: Wenxiu Lv and colleagues from the Patients and methods Selection of patients In this study, we reviewed the medical records of , consecutive children with rel/ref AML who received HDS at the first Affiliated Hospital of the University of Science and Technology of China from September , to July All patients with newly diagnosed rel/ref AML were younger than , years of age. The diagnosis was based on the published criteria (16). The choice of frontline treatment for HDS was made by the patients and their guardians, from whom informed consent was obtained according to the Declaration . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.